Share This Page
Drugs in ATC Class M01AA
✉ Email this page to a colleague
Drugs in ATC Class: M01AA - Butylpyrazolidines
| Tradename | Generic Name |
|---|---|
| AZOLID | phenylbutazone |
| BUTAZOLIDIN | phenylbutazone |
| PHENYLBUTAZONE | phenylbutazone |
| OXYPHENBUTAZONE | oxyphenbutazone |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class M01AA (Butylpyrazolidines)
ATC Class M01AA (butylpyrazolidines) covers mainly the NSAID active ingredient phenylbutazone and its closely linked brand/product formats in global markets. The patent landscape is dominated by older small-molecule composition and method patents, with most major markets now in the post-expiry regime, leaving formulation/process patents and data exclusivity / regulatory exclusivity as the main protectors of product differentiation. Competitive dynamics are shaped by generic availability, price compression, and local reimbursement rules, while future IP pressure is primarily from late-formulation and supply-chain process claims rather than brand-new molecular entities.
Which butylpyrazolidines are in ATC M01AA and where are they sold?
ATC M01AA is a therapeutic class for anti-inflammatory and analgesic NSAIDs. In practice, the market is centered on phenylbutazone formulations (oral solids, in some countries injectable or combination products), sold under multiple national brand names.
What is the core active ingredient in M01AA?
- Phenylbutazone (most market-relevant member of butylpyrazolidines)
How do markets segment?
- High-unmet-need segments: older safety-profile constrained use, limited in some geographies
- Established therapy markets: continued use in selected indications where guidelines lag or where alternative options exist but remain second-line
- Veterinary spillover: phenylbutazone has historical veterinary use patterns that can influence supply and manufacturing capacity in some regions
Geographies with the most observable commercial activity
- EU and UK: historically present due to genericization of phenylbutazone
- US: limited current availability compared with peak historical use; ongoing demand concentrated in specialty channels and older patient cohorts where supply persists
- Other regulated markets: fragmented by local approvals and generics
What drives market dynamics in M01AA (phenylbutazone) today?
The class is characterized by mature, commodity-like dynamics once patents and exclusivities clear.
Key market forces
- Generic price pressure: small-molecule NSAIDs face rapid generic erosion after the last composition/method patents expire
- Safety and reimbursement constraints: phenylbutazone historically faces prescribing restrictions in many systems, reducing total market growth even when supply is available
- Supply continuity risk: because the active ingredient is mature and supply can be concentrated in fewer manufacturers, some markets experience intermittent availability and channel-level pricing volatility
- Formulation differentiation: companies primarily compete on
- dose form (tablets versus capsules or other presentations),
- excipient systems for tolerability,
- manufacturing processes that can improve stability or reduce impurities.
Revenue exposure profile for an entrant
- When the newest IP is limited to formulation or process, the business case shifts from “exclusive product” to “defensible supply” or “protected labeling/format.”
When does phenylbutazone lose exclusivity in major markets?
Most phenylbutazone exclusivities are already exhausted in major regulatory jurisdictions because the core molecule was developed decades ago. In the current environment, “exclusivity” is more likely to be:
- orphan-like or data exclusivity from specific new formulations in narrow cases, or
- brand-specific local approvals where a manufacturer filed and obtained rights for a particular dosage form or strength.
What does “exclusivity” mean in practice?
- Regulatory exclusivity (data/market exclusivity) applies only to specific NDA-like approvals and new applications; phenylbutazone’s long maturity means many products are already generic and not tied to active brand exclusivity.
- Patent exclusivity is typically the longer tail, but in this class the tail is usually:
- formulation patents (composition of matter for specific formulations),
- polymorph/hydrate/solvate-specific claims (if any),
- manufacturing process patents.
Practical market timing conclusion
- The class is in a stage where timing disputes are less about initial active ingredient entry and more about:
- whether a given generic product infringes a formulation/process claim, and
- whether the branded product still maintains enforceable patents in the jurisdiction.
What patents protect butylpyrazolidines (phenylbutazone) and how many?
A complete, jurisdiction-specific count requires up-to-date docketing and Orange Book / national registers searches. Under current constraints, a defensible, precise enumeration of “how many patents cover” M01AA across jurisdictions cannot be produced without risking factual error.
High-confidence structural view of the patent estate:
- Composition of matter: old primary filings for phenylbutazone or basic salts/derivatives
- Formulation patents: tablets/capsules coatings, excipient blends, sustained release modifications (where pursued)
- Manufacturing process patents: granulation, drying, impurity controls, polymorph control methods
- Method-of-use patents: less common in mature NSAID classes unless tied to a specific indication, patient subset, or regimen
How strong is typical protection?
- In mature NSAID classes, protection strength is usually moderate to low against “ordinary” generic designs unless the claim scope is tightly linked to:
- a specific formulation composition,
- a specific polymorphic form,
- a specific manufacturing route.
What formulations are protected, and what generic entry risks exist for phenylbutazone products?
Generic entry risk in M01AA is generally tied to whether the generic’s product design maps to the branded product’s remaining formulation/process claims.
Common formulation IP targets
- Specific excipient systems for bioavailability or tolerability
- Coatings to manage dissolution timing and stability
- Impurity profile controls tied to specific synthesis or manufacturing steps
- Polymorph control for active ingredient consistency
Generic design-around paths
- Switch to alternative tablet cores, coatings, or granulation routes that avoid literal infringement
- Use a different polymorphic form if a branded polymorph is claimed
- Alter process parameters to fall outside process claim boundaries (where claims are method-defined and not broad product-by-process)
What patent litigation affects butylpyrazolidines (phenylbutazone)?
Without a live, jurisdiction-specific litigation dataset for the class, it is not possible to state specific, current disputes, case numbers, or settlement terms without creating factual inaccuracies.
Structurally, mature NSAID classes typically see:
- infringement contentions centered on formulation/process patents rather than active ingredient patents,
- challenges framed as non-infringement and invalidity,
- potential settlements where generics agree to a “design-around” or a delayed launch window.
What is the Orange Book status of M01AA (phenylbutazone) products?
A precise Orange Book listing status requires checking the FDA Orange Book for each marketed phenylbutazone product and its listed patents. A complete, error-free status summary cannot be produced under the current constraint.
Practical expectation for a US-facing IP strategy
- If a product is not listed in Orange Book for an active ingredient and NDA/BLA, it is not a standard Hatch-Waxman exclusivity and litigation scenario.
- If listed, the remaining patents are typically formulation/process-linked, not core molecule, given phenylbutazone’s age.
How does phenylbutazone compare with other NSAID classes on patent defensibility?
Relative to newer COX-2 selective or specialty NSAIDs, phenylbutazone defensibility is lower because:
- active ingredient novelty is historical,
- most primary patents have expired,
- generic manufacturing is widely established.
Competitive differentiation tends to shift to
- branded presentation,
- manufacturing quality and impurity control,
- logistics and availability,
- limited remnant IP on specific formats.
Who are the main players in phenylbutazone generics and branded supply?
A jurisdiction-level company roster requires verified sourcing from national registers, tenders, and FDA/EMA product pages. Providing named companies without live linkage would likely be inaccurate.
Typical player profile in mature M01AA
- multiple generic manufacturers with ANDA-like or local generic registrations,
- regional brands that persist for pharmacy-channel continuity,
- distributors where supply intermittency creates quasi-franchise dynamics.
What manufacturing and IP barriers affect new entry in M01AA?
Even when IP is weak, barriers can still exist.
Manufacturing barriers
- consistent impurity control,
- stability of finished dosage forms,
- process validation for scale-up,
- bioequivalence for reformulated products.
IP barriers
- enforceable formulation/process claims where remaining,
- local regulatory conditions tied to product history,
- any site-specific manufacturing process claims.
Key takeaways
- M01AA (butylpyrazolidines) is essentially a phenylbutazone-centered, mature NSAID market with generic-driven price dynamics.
- Core molecule exclusivity has largely run out; the remaining defensibility is typically formulation and process rather than new chemical entity patents.
- The most meaningful “entry risk” for generics is whether branded formulation/process patents still exist and whether the generic product maps to them.
- Litigation and Orange Book-driven Hatch-Waxman scenarios are possible in jurisdictions where patents are still listed/enforced, but the class is generally in a post-primary-patent landscape.
FAQs
What does ATC M01AA cover besides phenylbutazone?
ATC M01AA is mapped to butylpyrazolidines; in commercial practice, phenylbutazone is the dominant active ingredient associated with the class, with remaining members, if any, varying by country listing and marketing history.
Do formulation patents in older NSAIDs meaningfully delay generic entry?
Yes, when claims are specific to excipient/coating/procedure elements, they can drive design-around strategies and delayed launch negotiations, but they typically do not block entry indefinitely unless the branded product’s patent estate has multiple layers in force.
Are polymorph or hydrate patents common for phenylbutazone generics?
They can exist for older actives when companies invested in new solid forms or product-specific stability targets, but the frequency and enforceability vary by jurisdiction and by the particular marketed strength/dosage form.
How do reimbursement restrictions change the commercial value of M01AA products?
Restrictions reduce addressable patient volumes even if pricing is competitive, making supplier continuity and channel access more important than generic undercutting.
What patent strategy fits a new phenylbutazone formulation developer?
Focus on defensible, narrow formulation/process improvements that create tangible differentiation (stability, impurity control, tolerability or dissolution profile) while aligning with a regulatory pathway that supports enforceable claims in the intended jurisdictions.
References (APA)
- WHO Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
More… ↓
